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Abstract
Background
Hepatocellular carcinoma (HCC) continues to be a leading challenge in modern oncology.
Early detection via blood-based screening tests has the potential to cause a stage-shift at
diagnosis and improve clinical outcomes. Tumor associated autoantibodies (TA-AAbs)
have previously shown the ability to distinguish HCC from patients with high-risk liver dis-
ease. This research aimed to further show the utility of TA-AAbs as biomarkers of HCC and
assess their use in combination with Alpha-fetoprotein (AFP) for detection of HCC across
multiple tumor stages.
Methods
Levels of circulating G class antibodies to 44 recombinant tumor associated antigens and
circulating AFP were measured in the serum of patients with HCC, non-cancerous chronic
liver disease (NCCLD) and healthy controls via enzyme-linked immunosorbent assay
(ELISA). TA-AAb cut-offs were set at the highest Youden’s J statistic at a specificity
�95.00%. Panels of TA-AAbs were formed using net reclassification improvement. AFP
was assessed at a cut-off of 200 ng/ml.
Results
Sensitivities ranged from 1.01% to 12.24% at specificities of 95.96% to 100.00% for single
TA-AAbs. An ELISA test measuring a panel of 10 of these TA-AAbs achieved a combined
sensitivity of 36.73% at a specificity of 89.89% when distinguishing HCC from NCCLD
controls. At a cut-off of 200 ng/ml, AFP achieved a sensitivity of 31.63% at a specificity of
100.00% in the same cohort. Combination of the TA-AAb panel with AFP significantly
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Conclusions
A panel of TA-AAbs in combination with AFP could be clinically relevant as a replacement
for measuring levels of AFP alone in surveillance and diagnosis strategies. The increased
early stage sensitivity could lead to a stage shift with positive prognostic outcomes.
Introduction
Hepatocellular carcinoma (HCC) is one of the major challenges of modern oncology. It is the
sixth most common cancer worldwide and the fourth most common cause of cancer related
mortality [1]. The majority of cases occur in countries with high prevalence of viral hepatitis,
such as China, Japan and Egypt. However; rates in western countries are on the rise, attributed
to modern lifestyle changes such as increased alcohol consumption and poor diets.
Current American Association for the Study of Liver Disease (AASLD) recommendations
on surveillance of HCC are for ultrasound (US) imaging, with or without serum Alpha-feto-
protein (AFP) measurement for only the highest risk patients [2]. The largest randomised
control trial (RCT) for surveillance of HCC, using AFP and US, analysed 18,816 patients with
HBV infection or a history of chronic hepatitis from China and showed a clear benefit of
reduction in stage at diagnosis and mortality rates for the patients undergoing surveillance [3].
Presentation at earlier stage is linked with increased overall survival, however this is not the
only outcome required to implement screening strategies. A systematic review of HCC screen-
ing studies concluded that HCC screening by US is possible at a reasonable cost per quality
adjusted life year gained (QALY), but the authors highlight the need for an appropriate rando-
mised controlled trial (RCT) to confirm the results [4].
Whilst US based surveillance strategies have shown increased overall survival rates at an
acceptable cost per QALY, this type of imaging still suffers from a poor ability to detect early
stage HCC. A meta-analysis found the pooled sensitivity of US for early stage HCC to be 45%
at a high specificity of 92% with addition of AFP showing significant increase in early stage
sensitivity to 63% but with a trade-off in reduced specificity to 84% [5]. AFP testing alone also
struggles to detect early stage disease, with sensitivity typically below 50% [6,7] at specificities
of 80–94% in non-cancerous chronic liver disease (NCCLD) control groups [8].
Autoantibody (AAb) production to tumor associated antigens (TAAs) has been extensively
described in cancer patients [9] and is thought to be triggered by the proinflammatory nature
of tumor establishment and growth [10]. These tumor associated autoantibodies (TA-AAbs)
are primarily targeted at three forms of TAAs [10]; mutated proteins, aberrantly expressed
proteins and post-translationally modified proteins [11]. However, the exact role of AAbs,
and the immune system as a whole, in tumor control and progression is still debated [10].
The TAAs which produce an AAb response in HCC, and other malignancies, are wide
ranging and there are numerous studies that report the existence of different TAAs that can
elicit an AAb response [12–21]. In heterogeneous diseases, such as cancer, each subtype may
have its own set of unique biomarkers where the sensitivity of a single marker for the disease is
capped by the prevalence of that subtype [22–25]. It has also been shown that a panel of multi-
ple TAAs, rather than a solitary marker, can be useful in detecting HCC [15,26,27].
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This study aims to determine whether measuring autoantibodies against novel TAAs can
distinguish HCC patients from those with NCCLD and healthy controls. Assessment of
whether their measurement in combination with AFP may enhance diagnosis of HCC in
multiple disease stages, as previously demonstrated [28] will also be performed.
Materials and methods
Antigen selection
Antigens for the Discovery study were selected from two searches of Embase, Web of Science
and Medline: (i) a search for TAAs with existing TA-AAb data in HCC patients, and (ii) a search
for review papers of proteins that are highly associated with HCC (exact search terms are shown
in S1 Table). From these two searches, potential antigens that may elicit an AAb response were
identified based on the strength of their association with HCC or previously demonstrated
immunogenicity in HCC patients compared to controls. Antigens/TA-AAbs which overlapped
with our previous study [15] were removed from the review so as to increase the number of new
markers tested in this Discovery study. For the Confirmation study, six additional antigens with
high Youden’s J statistic were selected from the previous study [15] to analyse the potential com-
bination with leads from this Discovery study.
Protein production
The cDNA for the TAAs, were sub-cloned into modified pET21b or pET45b vectors to create
TAA-BirA-6xHis fusions, as previously described [29]. TAA fusion vectors plus a fusion tag
only control were transformed into BL21(DE3) Escherichia Coli competent cells [29] and cul-
tured as either 60 ml (Discovery study) or 500 ml (Confirmation study) volumes of TB over-
night express auto-induction medium (Novagen). For NY-ESO-1, EpCAM, VIM and Annexin
II, 500 ml cultures were used for the Discovery study instead of 60 ml. Proteins were purified
as previously described using either Ni Sepharose 6 Fast Flow resin (GE Healthcare) in 24 well
filter plates [29] (Discovery study) or 5 ml HisTrap FF crude prepacked columns (GE health-
care) [30] (Confirmation study). Proteins were analyzed for molecular weight and purity using
SDS-PAGE and Western Blotting and quantified by Bradford assay (Biorad).
ELISA
Autoantibodies were detected by ELISA according to previously described methods [30].
Briefly, TAAs plus a fusion tag only (BirA-6xHis) control were coated on to the wells of micro-
titer plates at either two (160 nM and 50 nM, Discovery study) or five concentrations (160 nM,
50 nM, 16 nM, 5 nM and 1.6 nM, Confirmation study) in duplicate. All patient specimens were
diluted 1 in 110 in blocking buffer and allowed to react with the immobilised TAAs. After plate
washing, the presence of IgG AAbs was detected using horseradish peroxidase-conjugated rab-
bit anti-human IgG (Dako), 3,30,5,50-tetramethylbenzidine chromogenic substrate (Merck) and
absorbance/optical density (OD) measured at 650 nm wavelength. Circulating AFP was mea-
sured using a commercially available ELISA (Aviva Systems Biology, OKBA00002).
Cohort
All patient specimens were collected with written informed consent at the respective collection
centres. Approval from the University of Nottingham Medical Research Ethics Committee was
also obtained. Ethical approval was obtained from the Trent Research Ethics Committee (10/
H0405/41) and the University of Nottingham Medical School Research Ethics Committee
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(BT/07/2007). Approval was also obtained from Nottingham University Hospitals through the
Comprehensive Local Research Network (CLRN) identification 43961.
Serum or plasma samples from three patient groups were used in this study: (i) patients
diagnosed with HCC (purchased from Indivumed GmbH, n = 100); (ii) control cohort of
patients with NCCLD, consisting of liver cirrhosis, alcoholic liver disease and chronic viral
hepatitis (collected by the Queens Medical Centre Biomedical Research Unit, Nottingham,
n = 115); (iii) control cohort of healthy individuals (collected as described previously [31],
n = 99). All HCC cohort patients were matched by both age and sex to the healthy control
cohort, however only gender matching to the NCCLD cohort was possible. The cohorts were
used for both the Discovery and Confirmation studies with the following modifications (i) Six-
teen samples in the NCCLD control cohort for the Discovery study (n = 99) were replaced for
the Confirmation study due to volume restrictions (ii) One sample in the HCC cohort for the
Discovery study (n = 99) was replaced and one removed for the Confirmation study due to vol-
ume restrictions. Demographics of all samples plus tumor/node/metastasis (TNM) stage [32]
of HCC samples are shown in Table 1. The HCC samples were obtained from a commercial
supplier with limited metadata provided, tumor stage was provided using the TNM system
Table 1. Demographics of the cohorts utilised in the Discovery and Confirmation ELISA.
Discovery Confirmationa
HCC
Number 99 98
Median age 63 63
Age range 30–91 30–91
% Male 69 69
TNM stage
1 35 35
2 21 20
3 21 21
4 2 2
N/A 20 20
Primary tumor size (cm)
Samples with data available 88 87
Mean 5.9 6.02
Min 0.4 0.4
Max 19 19
NCCLD
Number 99 99
Median age 57 50
Age range 30–89 30–82
% Male 69 69
Healthy
Number 99 99
Median age 63 63
Age range 30–87 30–84
% Male 69 69
aThe Confirmation cohort is primarily the same as the Discovery apart from the changes described in the text. N/
A = TNM stage data unavailable.
https://doi.org/10.1371/journal.pone.0232247.t001
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rather than BCLC and no data regarding overall liver status, such as Child-Pugh scores, were
available. Aetiology of the NCCLD controls is shown in S2 Table.
Data analysis
For the AAb ELISA, signal for the fusion tag only control protein was subtracted from the raw
OD value of each TA-AAb to correct for non-specific binding to bacterial contaminants. In
the Confirmation study ELISA, samples were excluded based on a visual assessment of the
duplicate titration curve data, if anomalous results were observed based on the surrounding
points of the curve which could not be resolved by the exclusion of a single replicate, or if high
binding was observed in the fusion tag only control wells. Cut-offs were optimised for differen-
tiating HCC from NCCLD controls. The sensitivity, specificity and Youden’s J statistic [33] for
HCC vs NCCLD controls were calculated for each TA-AAb at each sample OD. An algorithm
assigned cut-offs to each TA-AAb at 160 nM and 50 nM data points under the following crite-
ria: the OD value which gave the highest Youden’s J statistic�0.00 with a specificity�95%.
Panels of TA-AAbs were optimised using net reclassification improvement (NRI) [34] using a
custom Stata script (Stata, StataCorp LLC). Starting with the TA-AAb with the highest You-
den’s J statistic, TA-AAbs were added one at a time based on the highest NRI score of those
remaining, after each addition the NRI scores were recalculated until no further improvement
to the score of the panel could be achieved. For the AFP ELISA, samples above 200 ng/ml were
deemed positive for AFP and statistical analysis was performed in Stata. Significance of the
differentiation of HCC from NCCLD controls was assessed using the methods described by
Delong et al [35]. Significance of panel association with stage was analysed using logistic
regression and significance of sensitivity difference for individual HCC stages between tests
was analysed using McNemar’s test [36]. Specificity differences between groups was analysed
using Pearson Chi-squared analysis. Dot plots to show distribution of ODs by group were con-
structed in GraphPad Prism 6 (GraphPad Software). K-fold cross-validation was performed in
Stata for a choice of k = 5 [37].
Results
Antigen selection and production
After removal of antigens which overlapped with our previous study [15], the literature review
returned 64 unique antigens from 20 papers which have potential to generate TA-AAbs during
HCC tumorigenesis. After removing antigens not suitable for bacterial expression (carbohy-
drate antigens), 20 proteins from search (i) and 25 additional proteins from search (ii) were
selected. Of these 45 proteins, one (HGF) failed cloning and was therefore not included in
these studies, leaving 44 antigens to be used in the Discovery study ELISA (S3 Table). All pro-
teins were successfully expressed and purified which was confirmed by detection at the correct
molecular weight by Coomassie stained SDS-PAGE gels and/or Western blot.
Discovery study
For the ELISA of the Discovery cohort, cut-offs were assigned for all TA-AAbs for at least one
concentration, except CK19 which was excluded due to the fact that no appropriate cut-offs could
be identified. Sensitivities ranged from 1.00% to 7.10%, specificities from 96.00% to 100.00% for
the NCCLD samples and Youden’s J statistic from 0.00 to 0.07 (S3 Table). TA-AAbs to NY-ESO-
1 were the most discriminatory for differentiating HCC patients from NCCLD patients (Youden’s
J statistic 0.07, see Fig 1). NRI analysis with a Youden’s J statistic�0.00 established a panel of
eight TA-AAbs (Table 2). Dot plots representing the OD value for each TA-AAb in the panel are
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Fig 1. Dot plots of OD signals for each TA-AAb in the Discovery cohort panel. Error bars signify the mean with 95% confidence
intervals.
https://doi.org/10.1371/journal.pone.0232247.g001
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shown in Fig 1. Sensitivity for HCC of this panel was 28.28%, with specificities in the NCCLD
and healthy control groups of 93.94% and 87.88% respectively. Ability to distinguish HCC from
the NCCLD control group was significantly greater for the panel over the most discriminatory
single marker, NY-ESO-1 coated at 160 nM (p = 0.0015).
Confirmation study
The Discovery panel of eight TA-AAbs along with an additional seven leads from the Discov-
ery ELISA which were thought to be gender specific and six leads identified from previous
work [15] (21 in total, S4 Table) were assessed by ELISA for the Confirmation cohort. After
quality checks of the ELISA data, four of the healthy cohort control samples were excluded
from the analysis due to non-specific binding. TA-AAbs cut-offs were assigned for 15 of the 21
for at least one antigen plate coating concentration, six of the 21 (TA-AAbs to CDKN1B,
GBU4-5, NPM1, VIM, HSPD1 and HNRPL) had no ability to distinguish HCC patients from
controls for this cohort.
HCC sensitivities ranged from 1.02% to 12.24% for individual TA-AAbs, specificities ran-
ged from 95.96% to 100.00% for the NCCLD cohort and Youden’s J statistic from 0.00 to 0.09
(S4 Table). TA-AAbs binding to CAGE were the most discriminatory for distinguishing HCC
patients from those with NCCLD (Youden’s J statistic 0.09). NRI analysis of the data with a
Youden’s J statistic�0.00 established a panel of 10 TA-AAbs (Table 3). This panel had sensi-
tivity for HCC of 36.73% with specificities in the NCCLD and healthy control groups of
89.89% and 84.21% respectively. At a prevalence of 2.40% [38], the positive predictive value
(PPV) and negative predictive value (NPV) of the TA-AAb panel were 8.21% and 98.30%
respectively for HCC vs NCCLD. Area under the curve (AUC) was calculated as 0.616 for dif-
ferentiating HCC from NCLLD and five-fold cross validation of the AUC was 0.629 ± 0.062.
Specificity of the 10 TA-AAb panel was not significantly different between NCCLD patients
with hepatis B compared to hepatitis C (p = 0.72). Dot plots representing the OD value for
TA-AAbs to each antigen in the panel are shown in Fig 2. Ability to distinguish HCC from
NCCLD controls was significantly greater for the 10 TA-AAb panel over the most discrimina-
tory single marker, CAGE coated at 50 nM (p = 0.0002).
AFP ELISA
To compare the performance of circulating AFP and its potential combination with the 10
TA-AAb panel, levels were measured for the Confirmation cohort. Using a cut-off of 200 ng/
ml, the AFP ELISA had a sensitivity of 31.63% for HCC with specificities of 100.00% in both
Table 2. NRI Discovery study TA-AAb panel.
Addition order Plate coating antigen Antigen concentration (nM) Sensitivity (%) Specificity NCCLD (%) Specificity Healthy (%)
1 NY-ESO-1 160 7.07 100.00 98.99
2 EPCAM 50 5.05 98.99 93.94
3 HSPA4 50 4.04 100.00 100.00
4 VIM 160 7.07 97.98 93.94
5 HNRNPL 160 3.03 98.99 100.00
6 TF 160 2.02 100.00 100.00
7 AIF-1 50 2.02 100.00 100.00
8 MMP9 160 3.03 98.99 98.99
Panel of 1–8 28.28 93.94 87.88
Optimally performing TA-AAb ELISA panel determined by NRI analysis for the Discovery study.
https://doi.org/10.1371/journal.pone.0232247.t002
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the NCCLD and healthy control groups. Addition of AFP to the Confirmation study panel
of TA-AAbs for the Confirmation cohort raised sensitivity from 36.73% to 55.10% with no
change in specificity for either control group. At a prevalence of 2.40% [38], the PPV and
NPV of the TA-AAb panel plus AFP were 11.83% and 98.79% respectively. The Confirma-
tion study TA-AAb panel plus AFP was significantly better at distinguishing HCC from
NCCLD samples than the TA-AAb panel (p<0.0001) or AFP (p = 0.0122) alone. When sepa-
rated by AFP positivity, the TA-AAb panel had an overall sensitivity of 41.94% in AFP posi-
tive samples and 34.33% in AFP negative samples. TA-AAbs for CAGE remained the highest
sensitivity at 11.94% and AIF-1 was the only TA-AAb to be redundant in the AFP negative
group (S4 Table).
HCC stage analysis
The sensitivity of the TA-AAb Confirmation study panel, AFP and a combination of both
by stage are shown in Fig 3. TA-AAb panel sensitivity was not significantly associated with
increasing stage (p = 0.36) whereas AFP sensitivity was significantly associated with increasing
stage (p = 0.016). The combination of the TA-AAb panel and AFP was significantly associated
with increasing stage (p = 0.022). Although addition of AFP to the TA-AAb panel led to a sig-
nificant association of sensitivity with increasing stage, sensitivity for stage 1 and 2 (early
stage) HCC was significantly higher, at 45.45%, for the combined test than either the TA-AAb
panel, at 32.72%, (p = 0.0082) or AFP, at 23.63%, (p = 0.0005) alone. Sensitivity of the TA-AAb
panel alone for early stage samples in AFP negative patients was 27.59%. vs 46.15% for AFP
positive patients.
Discussion
The findings that single TA-AAb sensitivities for distinguishing HCC from high risk control
cohorts are low is not surprising and has been reported previously by ourselves and others
[15,20,39,40]. As with many cancers, HCC displays a high degree of molecular heterogeneity
attributed to the complex interactions of various underlying liver diseases [41] and therefore a
panel of biomarkers which reflects this heterogeneity may be of more use than one biomarker
alone. It is quickly becoming the consensus that biomarker test development for many cancers
Table 3. NRI Confirmation study TA-AAb panel.
Addition order Plate coating antigen Antigen concentration(nM) Sensitivity (%) Specificity NCCLD (%) Specificity healthy controls (%)
1 CAGE 50 12.24 96.97 90.53
2 NY-ESO-1 50 8.16 100.00 95.79
3 RalA 50 4.08 98.99 95.79
4 EpCAM 50 3.06 100.00 96.84
5 SOX2 160 3.06 100.00 98.95
6 AIF-1 160 1.02 100.00 100.00
7 MMP9 160 2.04 98.99 100.00
8 MAGE-A4 50 4.08 98.99 100.00
9 SALL4B 160 6.12 96.97 98.95
10 DDX3XN 160 5.10 97.98 97.89
Panel of 1–10 36.73 89.90 84.21
Optimally performing TA-AAb ELISA panel determined by NRI analysis for the Confirmation study.
N indicates the N-terminal tagged version of DDX3X, see S3 Table for more information.
https://doi.org/10.1371/journal.pone.0232247.t003
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Fig 2. Dot plots of OD signals for each TA-AAb in the Confirmation cohort panel. Error bars signify the mean with 95% confidence
intervals. N indicates the N-terminal tagged version of DDX3X, see S3 Table for more information.
https://doi.org/10.1371/journal.pone.0232247.g002
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Fig 3. Forest plots of the sensitivity of the Confirmation TA-AAb panel (A), AFP (B) and a combination of both
(C) by HCC TNM stage. N/A indicates sensitivity for samples of an unknown HCC stage.
https://doi.org/10.1371/journal.pone.0232247.g003
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will require the use of a panel of biomarkers from multiple molecular pathways. A TA-AAb
signature has previously been shown to be additive to circulating PSA levels to differentiate
prostate cancer from benign prostatic hyperplasia [42] and a combination of three circulating
tumor proteins with one TA-AAb has been shown to be useful for the early detection of non-
small cell lung cancer [43].
Fifteen antigenic leads from the Discovery study described here plus six identified in our
previous studies [15], twenty one in total, were produced on a larger scale and retested on pre-
dominantly the same cohort (Confirmation) to verify leads on an independent protein batch.
After this process, five leads identified during the Discovery study (CDKN1B, NPM1, VIM,
HSPD1 and HNRNPL) and one lead from our previous work (GBU4-5) no longer showed
ability to distinguish HCC from NCCLD samples. Combining individual TA-AAbs from the
remaining 15 into a panel, using NRI, established a panel of 10 TA-AAbs, with the 5 remaining
TA-AAbs made redundant due to overlap in ability to distinguish HCC from NCCLD con-
trols. This panel of 10 TA-AAbs significantly improved the ability to distinguish HCC from
NCCLD controls over any single TA-AAb alone with a sensitivity of 36.73% at a specificity of
89.90%. The Confirmation study panel of 10 TA-AAbs, identified by NRI, could distinguish
HCC patients of all stages with no significant difference in sensitivity between early and late
stage tumors. In comparison, the optimal panel in this study differs from the panel selected in
our previous study [15]. This is primarily due to differences in sample cohort as well as overlap
between patients positive for multiple TA-AAbs. Panel formation in relatively small patient
cohorts, such as these, can lead to exclusion of biomarkers which show complete overlap with
others in small patient cohorts but may not in a larger cohort. Results from this study and our
previous study should be considered when designing a larger study with independent training
and validation cohorts.
The 10 capture antigens for the TA-AAbs comprising the Confirmation study panel span
multiple pathways and are primarily overexpressed in HCC. MAGE-A4, NY-ESO-1 and
CAGE are cancer/testis antigens whose expression is normally restricted to germ cells [44],
and have been found to be commonly ectopically expressed in HCC as well as other malignan-
cies [45–48]. Overexpression of SOX2, EpCAM, RalA and SALL4B are associated with stem-
cell characteristics and epithelial-mesenchymal transition (EMT), this overexpression is seen
for many HCC patients [49–52]. Whilst not a marker of stemness, MMP9 is linked with EMT
as it plays a key role in degradation of the extracellular matrix and therefore by aiding the
escape of epithelial tumor cells from their location of origin, MMP9 expression has been linked
to the metastatic potential of HCC cells [53]. AIF-1 has been shown to promote proliferation
and migration of breast cancer cells [54,55], and whilst its role in HCC remains unknown,
increased mRNA levels in HCC tumor cells have been observed [56]. Presence of TA-AAbs to
the majority of these antigens in HCC patients have previously been described [15,20,57–59].
However, this is the first study to report the detection of autoantibodies to MMP9, AIF-1 and
EpCAM in HCC patients.
We observe that TA-AAb levels are similar for the individual groups baring a few outliers
(1–12%). This is a commonly observed feature of TA-AAb measurement within the literature
[25,60,61]. This is primarily due to the amplified nature of an antibody response and the rarity
of individual TA-AAbs to each TAA. As the antibody response is amplified rather than linked
to the size/activity of a tumor, population means will be similar for each TAA with the few out-
liers representing the true amplified response. Testing at a single serum dilution as performed
in this study potentially introduces limitations to the dynamic range of the assay. One serum
dilution was used in this study to simplify the procedure allowing interrogation of a large num-
ber of markers. The dilution used has previously been shown to give reproducible results
within a linear signal range in a TA-AAb based test for lung cancer [30]. Antigens were coated
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at multiple concentrations (50 and 160 nM) to enable selection of the optimal concentration
for this serum dilution.
The improved performance for detection of HCC of TA-AAbs in combination with AFP
compared with AFP alone has been demonstrated previously [28]. AFP performance in this
study was within the ranges reported in the literature [62]. It is commonly reported for AFP to
have low sensitivity in early stage HCC as AFP is only secreted by certain molecular subtypes
of HCC [63], and in those which do, AFP levels positively correlate with tumor size, number,
differentiation and vascular invasion [7]. Sensitivity of AFP was low when compared to the
TA-AAb panel for stage one HCCs (17% vs 29%) but improved for later stages. Combination
of AFP and the TA-AAb panel significantly increased the ability to distinguish HCC from
NCCLD controls compared to the TA-AAb panel or AFP alone. Sensitivity of the TA-AAb
panel plus AFP was significantly associated with increasing stage, however, the combination
still outperformed either the TA-AAb panel or AFP alone for detection of stage 1 and 2 HCC.
The object of this study was primarily discovery, to assess an additional and different set of
markers to our previous study [15]. This study therefore expands the knowledge base with
which to develop a panel of markers which, due to the limited size of the cohorts used to date,
will need to be verified by appropriately powered training and validation studies using inde-
pendent patient cohorts in future studies. The Confirmation assay allowed us to test a combi-
nation of the best markers from this Discovery study alongside lead markers from our
previous study [15] using independent batches of all the antigens. Despite the limited sample
set, K-fold cross-validation produced a similar AUC as the whole sample set, 0.629 and 0.616
respectively, with a small standard deviation of 0.062 indicating a low level of data overfitting.
The NCCLD samples in this study were obtained as part of a routine check for the status of
liver disease during a liver clinic with no follow-up data, therefore we do not know the number
of control samples that may have been false positives with undetected HCC at the time of sam-
pling. This could relate to an improvement in specificity in a clinical scenario, for example, if
the specificity is recalculated to account for a 2.40% prevalence of HCC in the NCCLD cohort
[38], specificity would rise to 90.54% for the TA-AAb panel and 91.00% for the TA-AAb plus
AFP panel. This study is also restricted by the use of HCC samples from a commercial biobank
with limited metadata which has prevented analysis of other clinically relevant factors such as
Child-Pugh score and BCLC staging. However, we believe the sample collection for this study
was an appropriate approach to gather data to inform the design of a study with prospective
collection including extensive metadata.
The semi-systematic review of the literature used for biomarker identification in this study
appears fit for purpose to expand on the data collected previously [15]. Future discovery stud-
ies could also encompass review of increasingly available next generation sequencing (NGS)
data to determine likely TAAs by detecting tumor specific mutations and aberrantly expressed
proteins which could elicit an immune response.
A cut-off of 200 ng/ml was chosen for AFP in this study. The HCC samples in this study
were obtained commercially with limited diagnosis data. Whilst AFP is not recommended as
a screening tool for HCC, it is often utilised in the monitoring of patients with liver disease.
Therefore, if AFP was measured during the monitoring of the patients, this could have led to a
bias towards patients with raised AFP, especially those with moderately raised AFP. A cut-off
of 200 ng/ml is associated with high specificity for HCC which should alleviate bias, as samples
with AFP greater than 200 ng/ml would likely have been diagnosed by traditional methods
therefore, this cut-off is more likely to be reproducible in a real-world scenario. There is debate
as to whether AFP is additive to US [64], however the differing biological pathways which trig-
ger TA-AAb production and the increased sensitivity for early stage HCC, may lead to the
TA-AAb plus AFP test being more complemental to US than AFP alone. HCC is very common
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in non-western countries where healthcare budgets are limited and access to health care clinics
is often restricted. Sensitivity of the TA-AAb panel plus AFP is significantly better than that
of AFP alone, as well as improving the sensitivity of detection of the earlier stages of disease
which have the best chance of cure but which are most difficult to detect by traditional screen-
ing strategies. The potential stage shift plus the low sample volume requirements and low cost
of the test, increase the likelihood of favourable cost-effectiveness. An alternative strategy
could be implemented with the TA-AAb panel used only in AFP negative patients, especially if
AFP is measured with a high specificity cut-off such as 200 ng/ml as used in this study. The
TA-AAb panel had a sensitivity of 34.33% in AFP negative patients, and 27.59% in early stage
AFP negative patients. This would therefore reduce the number of TA-AAb tests needed as
any AFP positive patients would not receive the TA-AAb test but will still allow for detection
of 27.59% of early stage tumors which would normally go undetected by AFP resulting in an
addition of 18.82% of early stage tumors detected over AFP alone.
This study has established a panel of TA-AAbs which in combination with AFP could have
clinical utility for aiding surveillance strategies or diagnosis of HCC. The early stage sensitivity of
the combination test (45.45%) was similar to that of ultrasound reported in the literature (45%)
[5], and can offer other advantages over US. One problem with US is operator variance depen-
dent on experience and equipment available, as well as variance associated with patient factors
such as underlying liver disease, cirrhosis status, gender and BMI [65]. Measurement of
TA-AAbs has previously been shown to exhibit low variance in results [66] and interpretation is
non-subjective as long as cut-off derivation is clearly explained and standardised. US is consid-
ered inexpensive when compared to other imaging modalities such as CT and MRI, however, as
the detection of TA-AAbs in this study is based on a simple ELISA based test employing capture
antigens produced in E. coli it offers an even cheaper alternative and indeed health economic
studies have demonstrated cost effectiveness of a TA-AAb test in lung cancer patients [67]. This
test as it stands does not outperform US so is unlikely to replace it completely, however follow-
up studies should be undertaken to analyse the combination of the two tests in order to assess
potential improvement in sensitivity.
This study has enabled identification of a TA-AAb panel ELISA which can distinguish
HCC patients from NCCLD and healthy patients and may be additive to AFP for the detection
of early stage disease. This work lays the foundations for further technical and clinical valida-
tion in independent cohorts to avoid bias and demonstrate clinical utility.
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